|
|
Article: Pfizer Receives Approval to Market Inspra for Congestive Heart Failure In Heart Attack Patients; Major Clinical Trial Showed 15 Percent Reduction In Deaths, Above and Beyond Current Therapies.
- Article from:
- PR Newswire
- Article date:
- October 8, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration to market Inspra(TM) (eplerenone tablets) for the treatment of congestive heart failure in patients who have had a heart attack.
Inspra, an aldosterone blocker, works by inhibiting the effects of aldosterone, a hormone that may contribute to the development and progression of hypertension and congestive heart failure (CHF), including damage to blood vessels, kidney and the heart.
CHF is a common progressive disease that often occurs when the heart muscle is weakened after it has been injured from a heart attack or high blood pressure. It is estimated that ...